Prometheus Biosciences, Inc.
RXDX
Rang in aandelen
#3256
Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused... Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused on discovering, developing, and commercializing innovative therapeutics and complementary diagnostic products, mainly targeting inflammatory bowel diseases (IBD). Its flagship therapeutic candidate, PRA023, is a humanized IgG1 monoclonal antibody currently undergoing Phase IIa clinical trials. This investigational treatment is being evaluated for its potential in addressing ulcerative colitis and Crohn's disease, both forms of IBD, as well as systemic sclerosis-associated interstitial lung disease. Beyond its lead asset, Prometheus maintains an active development pipeline featuring several other programs targeting IBD and other immune-mediated conditions: PR600: An anti-tumor necrosis factor monoclonal antibody (mAb) for IBD. PR300: A small molecule G-protein coupled receptor modulator specifically for IBD. PR1100: An anti-cytokine receptor mAb with applications in IBD and various other immune disorders. PR1800: An anti-chemokine mAb focused on IBD. PR2100: An anti-inflammatory cytokine mAb also aimed at IBD. Furthermore, the company has forged key alliances, including a diagnostic development and collaboration pact with Takeda Pharmaceutical Company Limited, a co-development and manufacturing arrangement with Dr. Falk Pharma GmbH, a licensing agreement with Cedars-Sinai Medical Center, and a strategic partnership with Millennium Pharmaceuticals, Inc. Tracing its origins, the company was initially incorporated in 2016 as Precision IBD, Inc., before rebranding to Prometheus Biosciences, Inc. in October 2019. Its corporate headquarters are situated in San Diego, California.
Aandeelprijs
$199.92
Laatst gesynchroniseerd: 2023-06-15
Marktkapitalisatie
$5.39B
Verandering (1 dag)
0.09%
Verandering (1 jaar)
0.00%
Land
US
Handel Prometheus Biosciences, Inc. (RXDX)
Categorie
Healthcare
Operationele marge voor Prometheus Biosciences, Inc. (RXDX)
Operationele marge op October 2026 TTM: -2,140.96%
Volgens de meest recente financiële rapporten en aandelenkoers van Prometheus Biosciences, Inc. is de huidige operationele marge (TTM) -2,140.96%. Eind 2021 had het bedrijf een operationele marge van -2,806.10%.
Geschiedenis van de operationele marge van Prometheus Biosciences, Inc. van 2014 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | -2,140.96% | 0.00% |
| 2022 | -2,140.96% | -23.70% |
| 2021 | -2,806.10% | 18.89% |
| 2020 | -2,360.21% | 65.25% |
| 2019 | -1,428.26% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | -100.00% |
| 2014 | -26,565.93% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 38.59% | -100.02% |
US
|
|
| -149.01% | -99.93% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 28.81% | -100.01% |
NL
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.